Working… Menu

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03876769
Recruitment Status : Recruiting
First Posted : March 15, 2019
Last Update Posted : May 27, 2021
Children's Oncology Group
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 26, 2026
Estimated Study Completion Date : December 21, 2027
Publications automatically indexed to this study by Identifier (NCT Number):